HR 7693 · in committee · niche
Leo’s Law
- healthcare
What this bill does
- This bill extends market exclusivity periods for orphan drugs by 180 days if applications were submitted during COVID-19.
- Drug manufacturers producing treatments for rare diseases benefit from extended exclusive market access.
- The extension applies retroactively to applications submitted during the COVID-19 emergency period.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How would a 180-day market exclusivity extension affect drug prices and accessibility for patients with rare diseases?
- 02
What evidence supports the claim that COVID-19 delays in orphan drug approval justify retroactive exclusivity extensions?
- 03
Which pharmaceutical companies would benefit most from this retroactive provision, and how does that align with orphan drug policy goals?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · D-NJ-5
Josh Gottheimer
Citizen cosponsors
0
In Congress
1/ 435
House Reps cosponsoring
Introduced 2026-02-25
Joining the bill
Legislative timeline
2026-02-25 · house · IntroReferral
Referred to the House Committee on Energy and Commerce.
2026-02-25 · IntroReferral
Introduced in House
2026-02-25 · IntroReferral
Introduced in House
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.